Latest revenue
$66.4M
as of 2026-03-31
Latest net income
—
as of 2026-03-31
Net margin
—
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $89.9M
- Enterprise value
- $89.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.98
- 52-wk low
- $0.27
- Beta
- —
- Shares out
- 199.7M
5-year trend
What this company does
Item 1. Business Overview We are a vertically integrated, multi-state cannabis operator engaged in retail, distribution, cultivation, and processing operations in both medical and adult-use markets. We are focused on building a diverse portfolio of cannabis assets through opportunistic investments and pursuing application opportunities in attractive limited license jurisdictions. We have targeted assets in highly populated, limited license medical markets that are on a trajectory toward adult-use legalization, including Pennsylvania, markets that are in the process of transitioning to adult use, namely Virginia, and limited license, large adult-use markets, such as Illinois, Massachusetts,…
AI summary unavailable — showing raw filing excerpt
Generated from JUSHF's filing dated 2026-03-31
Key risks
Item 1A. Risk Factors Summary of Risk Factors The Company is subject to numerous risks and uncertainties, any of which could have a significant or material adverse effect on our business, financial condition, liquidity or consolidated financial statements. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks we face, can be found below under the heading “Risk Factors” and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC, before making a decision to invest in our Subordinate Voting Shares. Risks Related to Our…
AI summary unavailable — showing raw filing excerpt
Generated from JUSHF's filing dated 2026-03-31
Profitability
Gross margin
43.4%
5.6%Operating margin
1.8%
56.3%Net margin
-24.2%
66.1%Return on equity
1044.6%
344.1%Return on assets
-14.0%
63.2%Leverage
Debt / equity
-4.66×
52.3%Long-term debt / equity
-1.73×
52.7%Debt / assets
127.3%
14.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $66.4M | +4.1% | — | — | — |
Q4 2025 2025-12-31 | $68.3M | +3.8% | — | — | — |
Q3 2025 2025-09-30 | $65.7M | +6.6% | — | — | — |
Q2 2025 2025-06-30 | $65.0M | +0.7% | — | — | — |
Q1 2025 2025-03-31 | $63.8M | -2.5% | — | — | — |
Q4 2024 2024-12-31 | $65.9M | — | — | — | — |
Q3 2024 2024-09-30 | $61.6M | -5.8% | — | — | — |
Q2 2024 2024-06-30 | $64.6M | -2.8% | — | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Medicinal Chemicals & Botanical Products · SIC 2833
Your notes
Keep private notes on JUSHF — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns JUSHF
No institutional holdings on file for JUSHF yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once JUSHF's latest filing finishes processing.